These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Shankar GM; Abedalthagafi M; Vaubel RA; Merrill PH; Nayyar N; Gill CM; Brewster R; Bi WL; Agarwalla PK; Thorner AR; Reardon DA; Al-Mefty O; Wen PY; Alexander BM; van Hummelen P; Batchelor TT; Ligon KL; Ligon AH; Meyerson M; Dunn IF; Beroukhim R; Louis DN; Perry A; Carter SL; Giannini C; Curry WT; Cahill DP; Barker FG; Brastianos PK; Santagata S Neuro Oncol; 2017 Apr; 19(4):535-545. PubMed ID: 28170043 [TBL] [Abstract][Full Text] [Related]
3. BAP1 mutations in high-grade meningioma: implications for patient care. Shankar GM; Santagata S Neuro Oncol; 2017 Oct; 19(11):1447-1456. PubMed ID: 28482042 [TBL] [Abstract][Full Text] [Related]
4. High-grade meningiomas: biology and implications. Bi WL; Prabhu VC; Dunn IF Neurosurg Focus; 2018 Apr; 44(4):E2. PubMed ID: 29606053 [TBL] [Abstract][Full Text] [Related]
5. Giant Pediatric Rhabdoid Meningioma Associated with a Germline BAP1 Pathogenic Variation: A Rare Clinical Case. Ravanpay AC; Barkley A; White-Dzuro GA; Cimino PJ; Gonzalez-Cuyar LF; Lockwood C; Halasz LM; Hisama FM; Ferreira M World Neurosurg; 2018 Nov; 119():402-415. PubMed ID: 29981911 [TBL] [Abstract][Full Text] [Related]
6. Pediatric clear cell meningioma involving the middle cranial fossa in the context of NF2 and SMARCE1 mutations. Libert DM; Prayson RA Ann Diagn Pathol; 2020 Jun; 46():151516. PubMed ID: 32311644 [TBL] [Abstract][Full Text] [Related]
7. Germline and somatic mutations in meningiomas. Smith MJ Cancer Genet; 2015 Apr; 208(4):107-14. PubMed ID: 25857641 [TBL] [Abstract][Full Text] [Related]
8. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis. Louvrier C; Pasmant E; Briand-Suleau A; Cohen J; Nitschké P; Nectoux J; Orhant L; Zordan C; Goizet C; Goutagny S; Lallemand D; Vidaud M; Vidaud D; Kalamarides M; Parfait B Neuro Oncol; 2018 Jun; 20(7):917-929. PubMed ID: 29409008 [TBL] [Abstract][Full Text] [Related]
9. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Katz LM; Hielscher T; Liechty B; Silverman J; Zagzag D; Sen R; Wu P; Golfinos JG; Reuss D; Neidert MC; Wirsching HG; Baumgarten P; Herold-Mende C; Wick W; Harter PN; Weller M; von Deimling A; Snuderl M; Sen C; Sahm F Acta Neuropathol; 2018 Jun; 135(6):955-963. PubMed ID: 29627952 [TBL] [Abstract][Full Text] [Related]
10. Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. Sievers P; Sill M; Blume C; Tauziede-Espariat A; Schrimpf D; Stichel D; Reuss DE; Dogan H; Hartmann C; Mawrin C; Hasselblatt M; Stummer W; Schick U; Hench J; Frank S; Ketter R; Schweizer L; Schittenhelm J; Puget S; Brandner S; Jaunmuktane Z; Küsters B; Abdullaev Z; Pekmezci M; Snuderl M; Ratliff M; Herold-Mende C; Unterberg A; Aldape K; Ellison DW; Wesseling P; Reifenberger G; Wick W; Perry A; Varlet P; Pfister SM; Jones DTW; von Deimling A; Sahm F; Acta Neuropathol; 2021 Feb; 141(2):281-290. PubMed ID: 33319313 [TBL] [Abstract][Full Text] [Related]
11. A new amplicon-based gene panel for next generation sequencing characterization of meningiomas. Mawrin C; Koch R; Waldt N; Sandalcioglu IE; Braunsdorf WEK; Warnke JP; Goehre F; Meisel HJ; Ewald C; Neyazi S; Schüller U; Kirches E Brain Pathol; 2022 Mar; 32(2):e13046. PubMed ID: 35213080 [TBL] [Abstract][Full Text] [Related]
13. Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas. Smith MJ; Wallace AJ; Bennett C; Hasselblatt M; Elert-Dobkowska E; Evans LT; Hickey WF; van Hoff J; Bauer D; Lee A; Hevner RF; Beetz C; du Plessis D; Kilday JP; Newman WG; Evans DG J Pathol; 2014 Dec; 234(4):436-40. PubMed ID: 25143307 [TBL] [Abstract][Full Text] [Related]
14. Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Smith MJ; O'Sullivan J; Bhaskar SS; Hadfield KD; Poke G; Caird J; Sharif S; Eccles D; Fitzpatrick D; Rawluk D; du Plessis D; Newman WG; Evans DG Nat Genet; 2013 Mar; 45(3):295-8. PubMed ID: 23377182 [TBL] [Abstract][Full Text] [Related]
15. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689 [TBL] [Abstract][Full Text] [Related]
16. Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes. Zhang X; Jia H; Lu Y; Dong C; Hou J; Wang Z; Wang F; Zhong H; Wang L; Wang K Discov Med; 2014 Dec; 18(101):301-311. PubMed ID: 25549701 [TBL] [Abstract][Full Text] [Related]
17. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation. Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203 [TBL] [Abstract][Full Text] [Related]
18. SMARCE1 mutation screening in classification of clear cell meningiomas. Smith MJ; Ahn S; Lee JI; Bulman M; Plessis DD; Suh YL Histopathology; 2017 Apr; 70(5):814-820. PubMed ID: 27891692 [TBL] [Abstract][Full Text] [Related]
19. Loss of SMARCE1 expression is a specific diagnostic marker of clear cell meningioma: a comprehensive immunophenotypical and molecular analysis. Tauziede-Espariat A; Parfait B; Besnard A; Lacombe J; Pallud J; Tazi S; Puget S; Lot G; Terris B; Cohen J; Vidaud M; Figarella-Branger D; Monnien F; Polivka M; Adle-Biassette H; Varlet P Brain Pathol; 2018 Jul; 28(4):466-474. PubMed ID: 28474749 [TBL] [Abstract][Full Text] [Related]
20. SMARCB1 mutations are not a common cause of multiple meningiomas. Hadfield KD; Smith MJ; Trump D; Newman WG; Evans DG J Med Genet; 2010 Aug; 47(8):567-8. PubMed ID: 20472658 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]